Non-small-cell lung cancer: Should histology guide chemotherapy treatment?

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1608-1609

  Bennouna, J ^a   Senellart, H ^a   Douillard, J Y ^a  

^a CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PEMETREXED;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CHEMOSENSITIVITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TREATMENT DURATION; TUMOR CLASSIFICATION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; HUMANS; LUNG NEOPLASMS;

EID: 69849105195     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp376     Document Type: Article

References (4)

1. Tan EH, Rolski J, Grodzki T et al. Global Lung Oncology Branch trial 3 (GLOB3): Final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2009; 20: 1249-1256.
2. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-3551.
3. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007; 99: 847-857.
4. Pirker R, Szczesna A, von Pawel J et al. FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26 (Suppl): (Abstr 3).